What Does Global Health Justice Look Like With a Seven-Figure Drug?
By Kevin Doxzen and Diana M. Bowman,
Slate
| 09. 22. 2021
Over the past decade, our ability to alter the human genome has rapidly improved, largely due to advancements in genome editing technologies like CRISPR. Scientists are vigorously pursuing the ultimate goal of making any change to any DNA sequence in any cell of the body. The versatility of these tools has opened the door to treating a range of debilitating diseases, from prevalent neurological conditions to rare forms of cancer. Yet, alongside promising therapeutic applications, we should be worried about the potential unethical and inequitable uses of these technologies.
Universal concern over the potential use and misuse of genome editing reached a peak in 2018 following the surprise announcement of the first edited babies. He Jiankui, a professor overseeing a university lab in China, publicly disclosed his efforts to engineer HIV immunity into human embryos. The international scientific community decried He’s experiment, and the Chinese government eventually filed criminal charges against this rising young scientist. He Jiankui is currently serving a three-year prison term after a Chinese court found him guilty of “illegal medical practice”.
Criticized as...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...